Journal of Blood Disorders & Transfusion

Maria Giuseppina Onesti

Publications

• Case Report
  Sweet's Syndrome as a Possible Consequence of Azacitidine Subcutaneous Administration in IPSS Intermediate-2 Myelodysplastic Syndrome
  Author(s): Antonietta Troccola, Pasquale Fino, Liliana De Santo, Federico Corrias, Paola Parisi, Massimo Breccia, Corrado Girmenia and Maria Giuseppina OnestiAntonietta Troccola, Pasquale Fino, Liliana De Santo, Federico Corrias, Paola Parisi, Massimo Breccia, Corrado Girmenia and Maria Giuseppina Onesti
  
  Sweet’s Syndrome (SS) is also called “acute febrile neutrophilic dermatoses”. The salient features are pyrexia, elevated neutrophil count, painful red skin lesions and a dense and diffuse dermal infiltrate consisting predominantly of mature neutrophils. We describe the clinical course of an 69-year-old women with myelodsysplastic syndrome who developed rapidly ulcerative skin lesion on whole right arm. Skin biopsy confirmed the diagnosis of Sweet syndrome. It is a peculiar case because the patient received azacitidine and developed Sweet’s Syndrome. The optimal treatment has not been defined. Systemic corticosteroids are the "gold standard" therapy for SS. Other firstline systemic treatments for SS are potassium iodide and colchicines. The lesion presented advanced dressings and was targed as having an hith degree of difficulty to cure. The use of Hyaff, an est.. View More»
  DOI: 10.4172/2155-9864.1000300

  Abstract PDF